Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 2

Prospective Observational Trial of Two Neoadjuvant Hypofractionated Radiotherapy Regimens Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas

NCT ID: NCT04506008Sponsor: Vanderbilt-Ingram Cancer CenterLast updated: 2025-03-28

Summary

The trial will use neoadjuvant hypofractionated radiotherapy followed by surgical resection in the treatment for soft tissue sarcoma. It will allow patients to be treated over a shorter course (5 or 15 days of radiation) compared to the traditional 5 week regimen. It is proposed that this will be possible without increasing the risk of wound complication or local recurrence compared with a traditional 5 week course of pre-operative radiation.

Detailed description

Study Objectives: Primary: * To investigate the efficacy of neoadjuvant hypo-fractionated radiotherapy (HRT) followed by surgical resection in the treatment of soft tissue sarcoma (STS) as measured by local control * Examine the side effect profile using Radiation Therapy Oncology Group (RTOG) and Common Terminology Criteria for Adverse Events (CTCAE) acute and late side effects criteria and major and minor post-operative complication rates. OUTLINE: Patients are assigned to 1 of 2 groups by the radiation oncologist. GROUP I (ULTRA-HYPOFRACTIONATION \[UH\]): Patients undergo HRT daily for a total of 5 fractions followed by surgery. GROUP II (MODERATE HYPOFRACTIONATION \[MH\]): Patients undergo HRT daily for a total of 15 fractions followed by surgery. After completion of study treatment, patients are followed up within 3 months, then every 3-6 months for a minimum of 2 years.

Arms & interventions

  • RadiationUltra-Hypo-fractionation Radiotherapy

    Five fractions of pre-operative radiation

  • ProcedureResection

    Surgery

  • OtherQuestionnaire Administration

    Ancillary studies

  • RadiationModerately-Hypo-fractionation Radiotherapy

    15 fractions of pre-operative radiation

Outcome measures

Primary

  • Local control rate

    Will be estimated with a Beta-Binomial model with Beta(0.5, 0.5) as the prior distribution. The median and a 95% credible interval of the posterior distribution will be reported.

    Time frame: Approximately 2 years

Secondary

  • Complication rate

    Time frame: Approximately 2 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Histologic diagnosis of a soft tissue sarcoma of extremity, pelvis, chest wall or trunk/abdominal wall (non-retroperitoneal location) * ECOG performance status 0-2 * Patient must be deemed able to comply with radiation treatment and surgery Exclusion Criteria: * History of prior radiation to the same area to be irradiated * Pregnancy * Active collagen vascular disease or patients genetically predisposed to increased radiation related side effects

Study locations (1)

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232

Recruiting
Vanderbilt-Ingram Service for Timely Access · Contact
Eric Shinohara, MD · Principal Investigator
Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas | Cancerify